# Divi's Laboratories (NSE: DIVISLAB) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/DIVISLAB · Pivot · prices to 22 Oct 2026

Divi's Laboratories (NSE: DIVISLAB) closed at ₹9,141.00 on 22 Oct 2026, up 0.46% on the day. With a market capitalisation of ₹2,43,222 Cr, it ranks 34th by market cap among the 4,183 NSE companies Pivot tracks (a large-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 94.6× trailing earnings, against a return on equity of 15.3% in FY26. Over the past year the share price has risen 39.5%. Its 52-week range is ₹5,647.50 (2 Apr 2026) to ₹9,740.00 (24 Sep 2026); the last close is 6.1% below the high. Promoters held 51.88% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹9,141.00 |
| Market cap | ₹2,43,222 Cr |
| P/E (trailing) | 94.6 |
| ROE | 15.3% (FY26) |
| ROCE | 19.4% (FY26) |
| Debt to equity | 0 |
| 52-week high | ₹9,740.00 (24 Sep 2026) |
| 52-week low | ₹5,647.50 (2 Apr 2026) |
| 1-year return | +39.5% |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹9,360 Cr | ₹2,191 Cr |
| FY24 | ₹7,845 Cr | ₹1,600 Cr |
| FY23 | ₹7,768 Cr | ₹1,823 Cr |
| FY22 | ₹8,960 Cr | ₹2,960 Cr |
| FY21 | ₹6,969 Cr | ₹1,984 Cr |
| FY20 | ₹5,394 Cr | ₹1,377 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 51.88%
- Foreign institutions: 20.20%
- Domestic institutions: 19.38%
- Non-institutions: 8.54%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Sun Pharmaceutical Industries](https://app.pivotnow.in/stock/SUNPHARMA) | ₹1,744.40 | ₹4,21,803 Cr | 36.5 | 13.7% |
| [Torrent Pharmaceuticals](https://app.pivotnow.in/stock/TORNTPHARM) | ₹4,604.50 | ₹1,75,551 Cr | 72.1 | 25.8% |
| [Zydus Lifesciences](https://app.pivotnow.in/stock/ZYDUSLIFE) | ₹1,123.00 | ₹1,13,217 Cr | 22.4 | 18.6% |
| [Apollo Hospitals Enterprise](https://app.pivotnow.in/stock/APOLLOHOSP) | ₹7,569.50 | ₹1,09,341 Cr | 56 | 20.5% |
| [Laurus Labs](https://app.pivotnow.in/stock/LAURUSLABS) | ₹2,010.10 | ₹1,08,185 Cr | 121.7 | 8.0% |
| [Cipla](https://app.pivotnow.in/stock/CIPLA) | ₹1,312.60 | ₹1,07,516 Cr | 27.3 | 11.3% |

## Questions and answers

### What is the share price of Divi's Laboratories today?

Divi's Laboratories (NSE: DIVISLAB) last closed at ₹9,141.00 on 22 Oct 2026. Its 52-week high is ₹9,740.00 and its 52-week low is ₹5,647.50.

### What is the market cap of Divi's Laboratories?

Divi's Laboratories' market capitalisation is ₹2,43,222 Cr (₹2.43 lakh Cr) at the 22 Oct 2026 close, ranking 34th among the NSE companies Pivot tracks.

### What is the P/E ratio of Divi's Laboratories?

Divi's Laboratories trades at a trailing P/E of 94.6. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 56.

### What is the ROE and ROCE of Divi's Laboratories?

Return on equity was 15.3% in FY26 and return on capital employed was 19.4% in FY26 (consolidated figures).

### Is Divi's Laboratories a debt-free company?

Divi's Laboratories is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### How has Divi's Laboratories stock performed over the last year?

Divi's Laboratories' share price has risen 39.5% over the past year, +23.7% over three months and −3.0% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Divi's Laboratories?

As of 30 Jun 2026: promoters 51.88%, foreign institutions 20.20%, domestic institutions 19.38%, non-institutions 8.54%.

### Who are Divi's Laboratories' competitors?

The listed Pharma & Healthcare companies closest to Divi's Laboratories by market cap are Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Zydus Lifesciences, Apollo Hospitals Enterprise, Laurus Labs and Cipla.

### Is Divi's Laboratories a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Divi's Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DIVISLAB against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.